Source link : https://www.newshealth.biz/health-news/azd0486-shows-good-efficacy-in-relapsed-refractory-follicular-lymphoma/
At the recent American Society of Hematology (ASH) annual meeting, data from a phase I trial of AZD0486 — a novel CD19xCD3 bispecific T-cell engager — showed high response rates and encouraging safety in relapsed/refractory follicular lymphoma patients, highlighting its potential role in sequencing strategies. In this third of four exclusive episodes, MedPage Today brought […]
Author : News Health
Publish date : 2025-01-02 18:00:00
Copyright for syndicated content belongs to the linked Source.